BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20930084)

  • 1. Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.
    Russwurm G; Heinsch M; Radkowski R; Erlemann R; Aul C; Haase S; Giagounidis A
    Blood; 2010 Oct; 116(14):2617-8. PubMed ID: 20930084
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
    Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
    Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
    [No Abstract]   [Full Text] [Related]  

  • 3. Dasatinib induces a response in chronic lymphocytic leukemia.
    Pitini V; Arrigo C; Altavilla G
    Blood; 2009 Jan; 113(2):498. PubMed ID: 19131559
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
    Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
    Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
    [No Abstract]   [Full Text] [Related]  

  • 7. On the assessment of dasatinib-induced autophagy in CLL.
    Krause G; Hallek M
    Leuk Res; 2011 Jan; 35(1):137-8. PubMed ID: 20947165
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes.
    Pitini VV
    Leuk Res; 2011 Jan; 35(1):32-3. PubMed ID: 20674019
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete morphologic and molecular remission after introduction of dasatinib in the treatment of a pediatric patient with t-cell acute lymphoblastic leukemia and ABL1 amplification.
    Crombet O; Lastrapes K; Zieske A; Morales-Arias J
    Pediatr Blood Cancer; 2012 Aug; 59(2):333-4. PubMed ID: 22689211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
    Amrein L; Soulières D; Johnston JB; Aloyz R
    Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
    Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
    Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
    [No Abstract]   [Full Text] [Related]  

  • 13. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.
    Veldurthy A; Patz M; Hagist S; Pallasch CP; Wendtner CM; Hallek M; Krause G
    Blood; 2008 Aug; 112(4):1443-52. PubMed ID: 18550857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Tucker DL; Mihailescu L; Riordan R; Rule S
    Br J Haematol; 2017 Jul; 178(1):153-155. PubMed ID: 27172457
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.
    Serpa M; Bendit I; Seguro F; Xavier F; Cavalcante M; Steinbaum D; Nardinelli L; Aldred VL; de Paula HM; Dorlhiac-Llacer PE
    Acta Haematol; 2010; 124(2):105-9. PubMed ID: 20720403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
    Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
    Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
    [No Abstract]   [Full Text] [Related]  

  • 17. Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia.
    Stagno F; Vigneri P; Del Fabro V; Fidilio A; Spina P; Massimino M; Messina A; Di Raimondo F
    Acta Haematol; 2010; 124(2):103-4. PubMed ID: 20689270
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
    Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
    Narita T; Kayukawa S; Yoshida T; Kusumoto S; Kataoka T
    Rinsho Ketsueki; 2013 Mar; 54(3):279-83. PubMed ID: 23676643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.